Expand PRLD Menu
PRLD MENU

PRLD Latest Press Releases

-- April 20, 2026 --

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering Globe Newswire 6:30 AM
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 6:00 AM

-- April 15, 2026 --

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer Globe Newswire 7:30 AM

-- March 17, 2026 --

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting Globe Newswire 4:31 PM

-- March 10, 2026 --

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 Globe Newswire 7:01 AM

-- February 5, 2026 --

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up Globe Newswire 9:26 AM

-- February 3, 2026 --

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor Globe Newswire 9:00 AM

-- December 16, 2025 --

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards Globe Newswire 12:18 PM

-- December 6, 2025 --

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs Globe Newswire 11:00 AM

-- November 26, 2025 --

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Globe Newswire 11:10 AM
Market Data Delayed 15 Minutes